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Traditional non-steroidal anti-inflammatory drugs (NS-
AIDs) inhibit cyclooxygenase that catalyzes the conversion 
of arachidonic acid into a variety of prostaglandins, throm-
boxanes and leukotrienes. NSAIDs are widely used for the 
treatment of various arthritides and pain syndromes.
1) The an-
ti-inflammatory and pain-relieving properties of NSAIDs are 
the result of prostaglandin synthesis inhibition mediated by 
cyclooxygenase-2 (COX-2) at the site of tissue injury, while the 
gastrointestinal tract complications are due to prostaglandin 
synthesis inhibition mediated by cyclooxygenase-1 (COX-1) in 
the gastrointestinal mucosa. The recognition of these 2 isoforms 
of COX led to the hypothesis that selective COX-2 inhibition 
would achieve the therapeutic benefits of non-selective NS-
AIDs without gastrointestinal toxicity. Celecoxib and rofe-
coxib were the first of these new agents that would treat pain 
without gastrointestinal toxicity. Large clinical trials con-
firmed that COX-2 inhibitors are associated with less gastro-
intestinal toxicity than non-selective NSAIDs. COX-2 inhibi-
tors have since become an enormous financial success.
2-5)
However, within months of rofecoxib’s approval in May 1999, 
the Vioxx Gastrointestinal Outcomes Research (VIGOR) tr-
ial reported a 5-fold increase in thromboembolic cardiovas-
cular events, primarily acute myocardial infarction, despite a 
50% reduction in serious gastrointestinal outcomes among pa-
tients treated with 50 mg/d of rofecoxib, compared to 1,000 
mg/d of naproxen.
2) In 2004, Merck withdrew rofecoxib from 
the market after its Adenomatous Polyp Prevention on Vioxx 
(APPROVe) trial showed a 2-fold increase in cardiovascular 
risk associated with treatment of rofecoxib 25 mg/d, compared 
to placebo. The Adenoma Prevention with Celecoxib (APC) 
trial comparing celecoxib with placebo reported a similar risk, 
especially at 400 mg/d or more. However, in Alzheimer’s Dis-
ease Anti-inflammatory Prevention Trial (ADAPT), celecoxib 
(400 mg/d) did not increase cardiovascular risk compared to 
naproxen.
6) 
The cardiovasular effect of COX-2 inhibition is complicated 
and is not yet fully understood. While non-selective NSAIDs 
including aspirin inhibit the formation of platelet-derived th-
romboxane and endothelial prostacyclin, COX-2 inhibitors 
preferentially suppress vasodilator and platelet inhibitory pro-
staglandins without blocking vasoconstrictive and platelet-
activating prostaglandins, which could result in a prothrombo-
tic state. In addition, the role of COX-2 inhibitors in accelerated 
atherogenesis may be modulated by renovascular hyperten-
sion, inhibition of vascular inflammation, improvement of en-
dothelial function and changes in artherosclerotic plaque st-
ability.
7-9) The safety aspects related to drug-eluting stent (DES) 
has been continuously addressed and dual antiplatelet thera-
py with aspirin and clopidogrel is recommended at least for 
one year following DES implantation. Moreover, many pa-
tients implanted with DES are elderly and often suffered from 
chronic arthritis. These patients are candidates for combined 
anti-inflammatory agent and dual antiplatelet therapy. Par-
ticularly, selective COX-2 inhibitors may be preferred in these 
patients, considering the implications of life-long aspirin main-
tenance therapy.
In the current review, Lee et al.
10) assessed whether celecoxib 
therapy would negate the antiplatelet effects of aspirin and 
clipidogrel in healthy, young-aged volunteers using light trans-
mittance aggregometry and arachidonic acid metabolite assay. Bum-Kee Hong   307
Volunteers were divided into 5 groups (n=8 per group) by treat-
ment regimen that included aspirin (100 mg/d), clopidogrel 
(75 mg/d) and celecoxib (400 mg/d): aspirin; celecoxib; as-
prin+celecoxib; aspirin+clopidogrel; and aspirin+clopidog-
rel+celecoxib. Celecoxib alone did not affect platelet aggre-
gation, and celecoxib combined with aspirin+clopidogrel did 
not affect inhibition of platelet aggregation induced by ade-
nosine diphosphase as well as collagen, suggesting that cele-
coxib would be administered safely to patients in whom dual 
antiplatelet therapy is needed. Previous studies showed that 
celecoxib did not affect aspirin’s inhibitory action of platelet ag-
gregation in patients with concurrent osteoarthritis and ische-
mic heart disease, as well as in healthy volunteers. These out-
comes support that of this review.
11)12) However, the outcomes 
of previous trials and that of this review can cause public con-
fusion. Is celecoxib different from rofecoxib in terms of cardio-
vascular risk profile? The answer is ‘partly yes’ as well as ‘partly 
no’. The cardiovascular effects of COX-2 inhibitors may dif-
fer due to distinct molecular structures with different levels of 
COX-1 or COX-2 selectivity, suggesting that cardiotoxicity 
is limited to certain drugs within the class, rather than due to a 
broad class effect. Kimmel et al.
13) found no evidence of COX-
2 inhibitor class effect for cardiovascular toxicity, but dem-
onstrated that rofecoxib use was associated with a statistical-
ly significant 2.72 increased odds of myocardial infarction, 
when compared to celecoxib use. On the other hand, the re-
leased data of the APC trial, stopped on the advice of the data 
safety monitoring board, showed that patients using cele-
coxib over long-term (average duration 3 years) at high dosages 
(400 mg/d or more) had a 2.5 to 3.4 fold increased risk for fa-
tal and non-fatal cardiovascular events, compared to those re-
ceiving placebo.
14) 
COX-2 can be a fascinating target for the prevention of re-
stenosis following PCI, because inflammation plays an im-
protant role in neointimal hyperplasia following vascular in-
jury and COX-2 is a key mediator of inflammation. Previous 
studies showed that celecoxib inhibits neointimal hyperpla-
sia following vascular injury by blocking Akt signaling, and 
possibly monocyte chemoattractant protein-1 (MCP-1) ex-
pression.
15)16)
This review would be good news for physicians as well as 
patients who have been suffered from chronic arthritis, and 
those require dual antiplatelet therapy following DES im-
plantation. However, there is inconsistency in the cardiovas-
cular safety data from various trials using selective COX-2 in-
hibitors and non-selective non-aspirin NSAIDs, and the evid-
ence is currently too limited to exclude the possibility of a 
COX-2 inhibitor class effect. Moreover, difference in cardio-
vascular safety between placebo and two principal COX-2 in-
hibitors, rofecoxib and celecoxib, became apparent only after 
several years of continuous treatment at high doses. Therefore, 
so far, the choice of anti-inflammatory regimens in patients 
who need antiplatelet therapy should be made to minimize 
the overall burden of adverse gastrointestinal and cardiovas-
cular outcomes. Further research is needed to elucidate the 
safety of long-term COX-2 inhibitor use, in conjunction with 
non-selective non-aspirin NSAIDs.
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